Radioiodinated antibody targeting of the HER-2/neu oncoprotein

被引：19
|
作者：
Xu, FJ
Yu, YH
Bae, DS
Zhao, XG
Slade, SK
Boyer, CM
Bast, RC
Zalutsky, MR
机构：
[1] UNIV TEXAS,MD ANDERSON CANCER CTR,DIV MED,HOUSTON,TX 77030
[2] DUKE UNIV,MED CTR,DEPT RADIOL,DURHAM,NC 27710
[3] DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710
来源：
NUCLEAR MEDICINE AND BIOLOGY | 1997年 / 24卷 / 05期
关键词：
c-erbB-2 (HER-2/neu); ovarian cancer; monoclonal antibody; radioiodination; tumor;
D O I：
10.1016/S0969-8051(97)00065-6
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
The HER-2/neu oncogene encodes a 185 kDa phosphoglycoprotein that is overexpressed in breast, ovarian and other cancers. Seven monoclonal antibodies reactive with this oncoprotein were labeled with I-131. In vitro experiments with SKOv3 9002-18 cells determined binding affinity, internalization and degradation. The biodistribution of these antibodies in comparison to I-125-labeled nonspecific antibody was measured in athymic mice with SKOv3 9002-18 ovarian carcinoma xenografts. Antibody 520C9 exhibited the highest and most specific retention in tumor, peaking at 17.4 +/- 5.6% ID/g at 24 h. (C) 1997 Elsevier Science Inc.
引用
收藏
页码：451 / 459
页数：9
相关论文
共 50 条
  • [41] HER-2/NEU Oncoprotein Serum Levels in Patients with Breast Cancer: Comparison with CEA and CA 15.3
    Molina, R.
    Auge, J. M.
    Munoz, M.
    Pahisa, J.
    Torne, A.
    Velasco, M.
    Farrus, B.
    Filella, X.
    TUMOR BIOLOGY, 2008, 29 : 34 - 34
  • [42] Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma
    Bermont, L
    Algros, MP
    Baron, MH
    Adessi, GL
    BREAST CANCER RESEARCH AND TREATMENT, 2000, 63 (02) : 163 - 169
  • [43] Her-2/neu oncoprotein serum levels in patients with breast cancer:: Comparison with CEA and CA 15.3
    Molina, R.
    Auge, J. M.
    Munoz, M.
    Pahisa, J.
    Torne, A.
    Velasco, M.
    Farrus, B.
    Filella, X.
    TUMOR BIOLOGY, 2007, 28 : 21 - 21
  • [44] Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma
    Laurent Bermont
    Marie-Paule Algros
    Marie-Hélène Baron
    Gérard L. Adessi
    Breast Cancer Research and Treatment, 2000, 63 : 163 - 169
  • [45] Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification
    Lal, P
    Salazar, PA
    Ladanyi, M
    Chen, BY
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2003, 5 (03): : 155 - 159
  • [46] Assessment of Her-2/neu gene amplification status in breast carcinoma with equivocal 2+ Her-2/neu immunostaining
    Mostafa, Naglaa A. E.
    Eissa, Saad S.
    Belal, Dalia M.
    Shoman, Soheir H.
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2011, 23 (01) : 41 - 46
  • [47] Phase 1 study of infusion of HER-2/neu specific T cells in patients with advanced stage HER-2/neu overexpressing cancers who have received a HER-2/neu vaccine
    Dang, Yushe
    Salazar, Lupe G.
    Coveler, Andrew
    Waisman, James
    Higgins, Doreen
    Childs, Jennifer
    Bates, Nicole
    Slota, Meredith
    Disis, Mary L.
    JOURNAL OF IMMUNOLOGY, 2009, 182
  • [48] Preclinical and clinical study of HER-2/neu-targeting cancer gene therapy
    Hung, MC
    Chang, JYJ
    Xing, XM
    ADVANCED DRUG DELIVERY REVIEWS, 1998, 30 (1-3) : 219 - 227
  • [49] HER-2/Neu overepression in gastric cancer
    Vergara, R.
    Torrazza, I.
    Castillo Fernandez, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] Testing to define the target Her-2/neu
    Menard, S
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 81 : S63 - S66
12345